Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer

Neil E. Martin1, Travis Gerke2, Jennifer A. Sinnott2,3, Edward C. Stack4,5,6, Ove Andrén7, Swen-Olof Andersson7, Jan-Erik Johansson7, Michelangelo Fiorentino4,8, Stephen Finn4,9, Giuseppe Fedele4, Meir Stampfer2,3, Philip W. Kantoff5, Lorelei A. Mucci2,3, and Massimo Loda4,5,6,10,11

Abstract

Assessing the extent of PI3K pathway activity in cancer is vital to predicting sensitivity to PI3K-targeting drugs, but the best biomarker of PI3K pathway activity in archival tumor specimens is unclear. Here, PI3K pathway activation was assessed, in clinical tissue from 1,021 men with prostate cancers, using multiple pathway nodes that include PTEN, phosphorylated AKT (pAKT), phosphorylated ribosomal protein S6 (pS6), and statin. Based on these markers, a 9-point score of PI3K activation was created using the combined intensity of the 4-markers and analyzed its association with proliferation (Ki67), apoptosis (TUNEL), and androgen receptor (AR) status, as well as pathologic features and cancer-specific outcomes. In addition, the PI3K activation score was compared with mRNA expression profiling data for a large subset of men. Interestingly, those tumors with higher PI3K activation scores also had higher Gleason grade (P = 0.006), increased AR (r = 0.37; P < 0.001) and Ki67 (r = 0.24; P < 0.001), and decreased TUNEL (r = −0.12; P = 0.003). Although the PI3K activation score was not associated with an increased risk of lethal outcome, a significant interaction between lethal outcome, Gleason and high PI3K score (P = 0.03) was observed. Finally, enrichment of PI3K-specific pathways was found in the mRNA expression patterns differentiating the low and high PI3K activation scores; thus, the 4-marker IHC score of PI3K pathway activity correlates with features of PI3K activation.

Implications: The relationship of this activation score to sensitivity to anti-PI3K agents remains to be tested but may provide more precision guidance when selecting patients for these therapies.

Introduction

The PI3K pathway is thought to be central in the development and progression of prostate cancer (1). PI3K pathway activation is associated with cellular proliferation, decreased apoptosis, decreased androgen receptor (AR) signaling, and disruption of DNA repair (2, 3). Agents targeting various points in the PI3K pathway are currently under development for the treatment of prostate cancer (4). The growing experience with targeted drugs in oncology, such as erlotinib, suggests that not all men will respond to pathway-targeted agents, highlighting the importance of identifying predictive markers. One possible approach to achieving this goal is to identify tumors with activation of the PI3K pathway.

Characterization of the PI3K pathway in prostate cancer has been typically performed by assessing the status of individual key pathway nodes, including the loss of the tumor suppressor PTEN (5), phosphorylation of AKT (6), and phosphorylation of the downstream marker ribosomal protein S6 (7). Previously used assays have included IHC (7), analysis of the phosphoproteome (8), mRNA profiling (9), characterization of copy number aberrations (CNA; ref. 10), and identification of exome mutations (11). The sample sizes, assay quality, and approaches used in prior studies have varied widely.

We hypothesized that given the heterogeneity in how the pathway might be activated in clinical samples, characterizing multiple nodes in the pathway simultaneously may provide a more global assessment of a tumor’s PI3K activity than focusing on individual markers. Further, we hypothesized that protein expression would be a robust way of assessing the cellular state of PI3K activity. Using archival tissue samples from men with prostate cancer, we assessed PI3K activation using an IHC score...
containing four markers. Lacking a gold standard for pathway activity, we compared this score with tumor features, clinical outcomes, and mRNA expression profiling.

Materials and Methods

Patients

We nested this study within three cohorts of men with localized prostate cancer: the Swedish Watchful Waiting Study (12), the U.S. Physicians’ Health Study (PHS; ref. 13), and Health Professionals Follow-up Study (HPFS; ref. 14). Details of the cohorts have been described elsewhere. Briefly, the Swedish group (1977–1998) is comprised of men diagnosed with prostate cancer incidentally on transurethral resection of the prostate (TURP) or benign prostatic hypertrophy enucleation who were followed initially with watchful waiting. The men have been followed for mortality through linkage with the Swedish Death Register through March 2008 and the included group represents a case–control set. We also included two U.S. cohorts: the PHS randomized trials of aspirin and supplements in the primary prevention of cardiovascular disease and cancer, and the HPFS cohort study of 51,000 U.S. male health professionals. From these two U.S. cohorts, tumor samples from participants diagnosed with prostate cancer between 1983 and 2004 were collected from the treating institution and medical records were abstracted for clinical information and outcomes. From HPFS and PHS, 5% and 9% of the samples, respectively, were from TURPs, with the remainder from prostatectomy. All men from PHS and HPFS were followed for the development of lethal disease, defined by distant metastases or prostate cancer–specific death through May 2011. A physician committee confirmed causes of death through medical record and death certificate review. This study was approved by the Institutional Review Boards of Harvard School of Public Health and Partners Healthcare.

Marker selection

We reviewed previously published IHC markers of PI3K pathway activity to select targets for inclusion with an emphasis on validated antibodies and significant prior literature supporting the marker’s inclusion. PTEN function, altered through mutation (11), CNA (10), or posttranslational regulation, leads to accumulation of the second messenger PIP3 and subsequent recruitment of AKT for activation. In mice with conditional pten loss in the prostate, premalignant lesions can develop, a process heightened to invasive and even metastatic disease with the addition of other molecular changes (1). Loss of tumor PTEN staining has been observed with increasing frequency in higher grade and stage prostate cancers (5, 15). At the cell membrane, AKT is phosphorylated by either PDK1 (Thr308) or mTOR kinase complex 2 (Ser473) and phospho-antibodies directed at phospho-AKT (pAKT) show reversal of activation with inhibition of the PI3K pathway (16). Further, prostate tumor expression of pAKT has been associated with higher grade disease (6) and worsened prognosis (17). Downstream of AKT, mTOR activates S6 kinase leading to phosphorylation of ribosomal protein S6 (pS6). Both in cell lines (16) and patient specimens (4), pS6 is lost with PI3K inhibition. In addition, loss of mTOR or akt1 in mice with conditional pten loss reduces the initiation of prostate cancer (18). Stathmin, a microtubule regulating phosphoprotein, has been associated with PTEN loss in vitro (19) as well as in human prostate (20, 21) and breast cancer (9). Stathmin expression is regulated by PI3K inhibitors (8, 9) and, in breast cancer, was identified as a robust marker of PTEN loss (9).

Immunohistochemistry

Hematoxylin and eosin slides were reviewed by study pathologists (M. Fiorentino, S. Finn, G. Fedele, and M. Loda) to identify tumor tissue and systematically assess Gleason grade. Using tumor tissue microarrays (TMA) constructed from triplicate 0.6-mm cores for each case, we performed IHC staining to assess tumor expression of cytoplasmic PTEN (Zymed cat. #18-0256; 1:200), cytoplasmic pAKT (Ser473; Cell Signaling Technology; cat. #4060; 1:50), cytoplasmic pS6 (Ser240/Ser244; Cell Signaling cat. #2215; 1:50), cytoplasmic stathmin (Cell Signaling Technology; cat. #3352; 1:50), and Ki67 (polyclonal anti Ki67 antibody; Vector Labs; 1:2,000) and AR (Upstate [Millipore]; cat. #06-680; 1:100). For each marker, a 4-μm section of the TMA was mounted on a glass slide, deparaffinized, and microwaved for antigen retrieval in citrate-based buffer. Diaminobezidine (DAB) was used to visualize the IHC, with hematoxylin as a counterstain. To estimate the percentage of cells undergoing apoptosis, we used the terminal deoxynucleotide transferase–mediated dUTP nick end labeling (TUNEL) assay with the ApoTag Peroxidase In situ kit (Chemicon International). Antibodies were routinely validated by Western blot analysis and have been published previously.

IHC interpretation

All interpretation of IHC was performed blinded to outcomes. TMA slides were analyzed using the Ariol instrument SL-50 (Applied Imaging), a semiautomated image analysis software system. Each core was reviewed by a study pathologist to ensure matching to the TMA map and to manually circle tumor and exclude normal prostatic glands. After appropriate thresholding for each TMA, image analysis was performed using the Ariol MultiStain Assay to generate the following variables: percentage of nuclei positive (Ki67) and average percentage of cytoplasm staining per cell, a measure that approximates the percentage of cells positive for cytoplasmic staining. For pAKT, pS6, and stathmin, a continuous value was obtained after averaging across the replicate cores. For AR, the Ariol and ChromaVision (ChromaVision Medical Systems, Inc.) systems were used. For PTEN, the Nuance system (CRi) was used. Histologic images were analyzed using a cytoplasmic algorithm, wherein multispectral imaging allows the software to segment the nuclei using the unmixed spectra of the nuclear counterstain (hematoxylin) and then assessing the DAB IHC stain in the cytoplasm (outside of the nucleus). A final score, based on the average percentage of the cytoplasmic tumor area that was positively stained, was determined from each set of three subject cores. This method has been shown to correlate highly with semiquantitative pathologist assessments and there is good correlation between the Ariol and Nuance platforms (22). For the TUNEL assay, every tumor core was evaluated manually to determine the number of positive cells among the total number of tumor cells with two study pathologists independently assessing these samples.

mRNA expression profiling

mRNA expression profiling data were available for 233 of the men from the Swedish cohort and 76 men from the PHS cohort, for whom we also had protein expression of the four markers. The RNA was extracted from archival specimens from the same tumor-
enriched nodule as the TMA cores or a nodule of the same Gleason grade. The techniques for RNA extraction and expression analysis using a custom 6,100 cancer-related gene panel have been previously reported (12).

Statistical methods

IHC assessment. We used quantile normalization to efficiently adjust for potential batch effects of protein expression staining across each of the TMAs using the limma package in R (23). Spearman correlations between markers were calculated. The continuous scores for PTEN, pAKT, pS6, and stathmin were divided into tertiles and assigned a value of –1, 0, or 1 for low, intermediate, and high staining, respectively. As loss of PTEN is associated with pathway activation, the high staining and low staining values were assigned –1 and 1, respectively. Next, we generated a composite score of PI3K activation by summing these tertile values for each case, resulting in a 9-point scale ranging from 3 to 4. We performed univariate and multivariate analyses correlating the IHC PI3K score to baseline characteristics. We divided into tertiles and assigned a value of 1, 2, or 3 for each case, resulting in a 9-point scale ranging from 1 to 3.

mRNA expression profiling. To examine the relationship between the IHC score and mRNA signatures of pathway activation, we combined the lowest three and highest three categories of scores to denote low and high PI3K activity, respectively. Gene sets significantly differentially expressed between these extreme cases were assessed using mean-rank gene set enrichment (24). In this analysis, we utilized all KEGG sets (n = 186) along with 13 extracted sets of genes from the literature associated with PI3K pathway activation (8, 9, 19, 25-34) and cell-cycle progression (35). To identify a set of genes differentially expressed between the cases in the extreme, we used the significance analysis of microarrays (SAM) approach (36). We applied the published signature of PTEN loss in breast cancer (9) to the extreme samples from our IHC score to determine an association of our score to existing mRNA signatures from the literature. To test the relationship of flux through the AR pathway to PI3K pathway activity (3), we investigated expression of a 17-gene AR signature (37) relative to our score. Our a priori hypothesis was that the biology of PI3K activation would be independent of sample source and we therefore combined the three cohorts in our primary analysis.

In an exploratory analysis, we used a published mRNA signature of PTEN loss in breast cancer (9) as a gold standard to determine which marker or combination of markers was most closely correlated with PI3K activity defined in this way. We compared all first-order combinations of markers to find the best-fitting model based on the Akaike information criterion.

Results

Cohort characteristics

The clinical and pathologic characteristics of the 1,021 prostate cancer patients for whom IHC staining data were available are shown in Table 1. The cohort had a median age of 68.2 years

<table>
<thead>
<tr>
<th>Year of diagnosis, median (IQR)</th>
<th>HPFS (n = 375)</th>
<th>PHS (n = 288)</th>
<th>Combined (n = 1063)</th>
<th>PHS (n = 76)</th>
<th>Swedish (n = 233)</th>
<th>Combined (n = 309)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT4 or N1 or M1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up, median (IQR), mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IHC Score, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (–4, –3, –2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate (–1, 0, 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High (2, 3, 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

aGleason missing on 1 from HPFS and 5 from the Swedish cohort.
bPSA missing from 64 in HPFS and 40 in PHS.
cStage missing in 23 from HPFS, 40 from PHS, and 2 from the Swedish cohort.
dIHC Score is the combined 4-marker IHC signature of PI3K activation.
eLethal outcome missing in 118 missing due to insufficient follow-up (minimum of 8 years without a lethal or metastatic event).
[interquartile range (IQR), 63.9–73.4] and more than half of cases were Gleason 7. Over a median follow-up of 144 months (IQR, 94–181), 204 (20%) of men had developed distant metastatic disease or had died of prostate cancer. We did not observe major differences between the U.S. and Swedish cohorts in terms of their baseline clinical and pathologic characteristics.

IHC score

Positive correlations in the staining between individual markers in the pathway (Fig. 1) were statistically significant but generally weak. The strongest correlations were between pAKT and stathmin \( r = 0.24; 95\% \text{ confidence interval (CI), } 0.18–0.30; P < 0.001 \) and pAKT and pS6 \( r = 0.23; 95\% \text{ CI, } 0.17–0.29; P < 0.001 \). A negative correlation between PTEN staining and other markers in the pathway was not observed.

We created a 9-point signature of PI3K pathway activation using the combined staining of PTEN, pAKT, pS6, and stathmin (Fig. 2A). Of the entire cohort, 2.3% and 1.7% fell into the lowest and highest categories, respectively, highlighting the rare concordance of all four markers defining pathway inactivation or activation. On univariate analysis, the score was not significantly associated with age, body mass index (BMI), or PSA at diagnosis, but was positively associated with increasing Gleason score \( (95\% \text{ CI, } 0.34–0.35; P = 0.003) \) and increased cellular proliferation as measured by Ki67 staining. Pearson correlation \( r = 0.24 \) \( (n = 964; 95\% \text{ CI, } 0.18–0.30; P < 0.001; \text{Fig. 2C}) \). On univariate analysis, a one-point increase in the score had an OR of 1.07 for lethality \( (95\% \text{ CI, } 0.98–1.17; P = 0.14) \). We found a significant interaction between Gleason, the score and lethality \( (P = 0.03) \). Compared with men with lower Gleason scores, the IHC score was more associated with lethal outcome for cases with Gleason scores of \( \geq 8 \) \( (\text{Fig. 2D}) \).

In the 309 cases for which we had both GEP and the 4-marker score, we assessed genes, and subsequently gene sets, differentially expressed between cases with low scores \( (−4 \text{ to } −2; 20\%) \) and high scores \( (2–4; 18\%) \). Using SAM analysis, the genes most differentially expressed between high and low IHC scores were PMAIP1, FANCC, RLF, RREB1, NUSAPI1, TK1, DPT, and WFS1 (Table 2). Only the cell-cycle progression gene set \( (35) \) significantly differentiated the two groups \( (P < 0.001) \), but to illustrate the remaining top 10, we have included them in Table 2. The second and third most differential sets were the KEGG mismatch repair and the set identified in PTEN-deficient breast samples \( (\text{ref. 9; Table 2}) \). Among the top 25 differential genes sets, there were three PI3K-specific \( (8, 9, 25) \) and three KEGG DNA-repair sets: mismatch repair, base-excision repair, and homologous recombination. Using the directional expression of 98 available genes from a signature of PTEN loss in breast cancer \( (9) \), we found the signature to be significantly associated with the low and high IHC scores \( (P = 0.006; \text{Fig. 2E}) \). Looking for correlation between individual mRNA and IHC expression, we found significant correlation for STMN1 \( r = 0.24; 95\% \text{ CI, } 0.13–0.34; P < 0.01 \) but not for PTEN \( r = 0.5 \), AKT1 \( r = 0.2 \), or RPS6 \( r = 0.3 \).

Figure 1.
Correlation plots of the normalized IHC staining plots for each marker along with the Spearman correlation coefficient.
Androgen receptor

In light of the previously reported reciprocal relationship between PI3K pathway activation and flux through the AR pathway (3), we assessed how the 4-marker IHC score correlated to AR staining (n = 657) and expression of 17 AR-targeted genes (37). As shown in Fig. 3A, the 4-marker IHC score was positively correlated

Figure 2.
The IHC score of PI3K pathway activation is associated tumor and clinical features suggestive of more aggressive disease: A, IHC staining for PTEN, pAKT, pS6, and stathmin in patterns reflecting high and low pathway activity; B, distribution of IHC scores by Gleason score; C, correlation between the IHC score and Ki67 staining; D, ORs for lethal outcome for a one-point increase in the initial 4-marker and refined 2-marker score by Gleason showing a significant interaction; and E, box plots for an mRNA signature of PI3K activation from breast cancer showing a statistically lower score in the low (1–4) IHC score cases relative those with a high (2–4) score.
with tumor AR staining, \( r = 0.37 \) (95% CI, 0.30–0.43; \( P < 0.001 \)).

Among the 309 cases for which we had mRNA expression, we observed no association between expression of the AR responsive gene signature and the IHC score (Fig. 3B). AR expression was not associated with expression of the 17-gene signature of AR signaling. AR expression relative to the tertile of IHC scores for all four markers along with clinical and pathologic features is shown in Fig. 3C. The heat map, ordered by 4-marker score, illustrates the overall pattern of IHC staining for the four markers relative to proliferation (Ki67), apoptosis (TUNEL), age at diagnosis, lethal- ity, and Gleason score.

IHC score refinement

We next sought to determine the relative importance of PTEN, pAKT, pS6, and stathmin in capturing activation of the PI3K pathway. Given its correlation with our 4-marker score, we assessed which marker, or set of markers, were most correlated with the signature from Saal and colleagues shown to be associ- ated with PTEN loss in breast cancer (9). Individually, both stathmin (\( r = 0.26; 95\% \text{ CI}, 0.15–0.36; P < 0.001 \)) and pAKT (\( r = 0.15; 95\% \text{ CI}, 0.04–0.26; P = 0.007 \)) were significantly correlated with the signature (Fig. 4A). Comparing all possible first-order models of fit, the model containing pS6 and stathmin was identified as most strongly correlating with the mRNA signature of PI3K activation. Using the same tertiles of staining of stathmin and pS6 used for the 4-marker score, we created a “refined” 5-point scale of PI3K activation with only these two markers.

As with the 4-marker score, the refined 2-marker score was positively correlated with Ki67 staining (\( r = 0.23; 95\% \text{ CI}, 0.17–0.29; P < 0.001 \)) but was not significantly associated with apoptosis (\( r = 0.02; 95\% \text{ CI}, –0.06–0.10; P = 0.6 \)). Also, similar to the 4-marker score, there was no significant association with age, PSA level, BMI, or the development of lethal disease. The 2-marker score was positively correlated with Gleason score (\( P = 0.002; \) Fig. 4B) and on univariate analysis, a one-point increase in the refined score had an OR of 1.08 for lethality (95% CI, 0.96–1.23; \( P = 0.20 \)). Similar to the relationship observed with the 4-marker score, the refined score and Gleason had a significant interaction with lethality (\( P = 0.008; \) Fig. 2D).

Discussion

Using IHC assessment of PTEN, pAKT, pS6, and stathmin, we developed a signature of PI3K pathway activation in prostate cancer. Lacking a gold standard marker in human tissue to compare to, we used mRNA expression, cellular proliferation, apoptosis, and correlation with clinical factors to support the interpretation that the combination of these four markers is capturing PI3K activity.

Several lines of evidence suggest that our IHC score is associated with PI3K activity. First, an increase in the IHC score was associated with tumor features previously suggested to be associated with PI3K pathway activation. We found that increased PI3K activation was associated with increasing Gleason score, a finding similar to prior studies in prostate cancer (5, 15, 16, 38, 39). Further, we found increased Ki67 staining among tumors with higher PI3K IHC scores, an anticipated biologic finding and one similar to prior studies. Increased PI3K activation was also significantly associated with decreased apoptosis, a finding in line with the known biology of the pathway (8).

Second, we found that genes differentially expressed between cases with high and low IHC scores were associated with cellular proliferation and DNA repair (Table 2). The PI3K pathway has been associated with DNA repair (40), including through mechanisms related to cell-cycle regulation (2). Additionally, pathway activation is correlated with cellular proliferation in vitro and in model systems as well as in clinical samples (41). Similar to the individual genes, the gene sets identified as differentiating those tumors with high and low IHC scores were enriched for processes associated with PI3K pathway activation. The most differentially expressed was the gene set associated previously with cell-cycle progression (35), although sets associated with PI3K activation, prostate cancer, and DNA repair were also highly represented. These findings are similar to other studies investigating genes differentially expressed between cells with and
without PI3K pathway activation (19, 28). Finally, the IHC score was directly correlated with an established mRNA signature of PTEN-deficient breast cancers (9).

The ability of PI3K pathway activation to predict clinical outcome after prostatectomy has depended on which marker was investigated and what outcome was studied; generally higher activation has been associated with a higher likelihood of disease recurrence following surgery (9, 15, 17, 38, 39, 42, 43). In our data, the IHC signature of PI3K activation was not significantly associated with the development of clinically relevant lethal disease on univariate analysis, although there was evidence of a significant interaction with Gleason with the trend toward the high PI3K activity being more associated with lethality in high Gleason grades. The implications of this are unclear, although this finding may support the rationale for the use of PI3K inhibitors in higher grade tumors. Further research will be required to determine whether high relative to low Gleason grade tumors rely on different pathways to drive prostate cancer mortality. Given the heterogeneity of the three populations and nonrandom manner in which cases were included in the cohorts, caution is warranted in interpreting the outcomes related to lethality in this study. Ultimately, our goal in this study was not to develop a new prognostic signature in prostate cancer but rather to move toward signatures that may be predictive of response to PI3K-targeted agents.

Figure 3.
The 4-marker IHC score for PI3K activation is positively correlated with AR staining; A, 4-marker IHC score of PI3K activation relative to AR staining; B, 17-gene mRNA signature of AR flux score in low (−4 to −2) and high (2−4) IHC score cases showing no significant differences; and C, heatmap of tertile of IHC staining all four marker with corresponding annotation of (top to bottom) Ki67, TUNEL, age at diagnosis, lethal outcome, Gleason score, and the 4-marker score.
PTEN IHC staining. One explanation for this inclusion of pS6 in this correlation are notable given that the signature in breast cancer (9). The absence of PTEN and the signature. The inclusion of stathmin is unsurprising, insofar as the combination of pS6 and stathmin staining best correlated to this extremes identi
cation score using pS6 and stathmin by Gleason score. It remains unclear which IHC markers and which combinations are most important for capturing PI3K activity, and therefore presumed inhibitor sensitivity, in archival prostate cancer samples. To explore this question, we used the mRNA signature of PI3K activity derived from breast samples (9) as a gold standard and investigated which IHC markers were most correlated to the extremes identified using that approach. We found that the combination of pS6 and stathmin staining best correlated to this signature. The inclusion of stathmin is unsurprising, insofar as this marker was found as the IHC target best correlated with the signature in breast cancer (9). The absence of PTEN and the inclusion of pS6 in this correlation are notable given that the signature was initially derived from clinical samples that lacked PTEN IHC staining. One explanation for this finding is the robustness of the antibodies for stathmin and pS6 in these archival samples relative to the other two markers. It is known, for example, that there are significant challenges with phosphor-
antibodies in the setting of differential fixation approaches (44), and pS6 appears to be more resistant to this effect compared with other markers (45). Additionally, there is reported variability in the quality of PTEN antibodies (46). A more recent PTEN antibody has been shown to have excellent performance in cell lines and clinical samples (15, 46). We have reviewed this newer antibody on a limited subset of these cases and found a staining to be highly concordant with our current PTEN antibody, so it is not clear that its use would change our results. In our data, there was no significant correlation between PTEN mRNA and IHC expression. In both the 4-marker and refined 2-marker scores, each constituent marker was given equal weighting. In our analysis, this was necessary, although arguably a true signature of pathway activation, or inhibitor sensitivity, would likely weight markers quite differently based on their individual contribution relative to a clinical outcome. With only a subset of the tumors having mRNA available, this aspect must be interpreted with appropriate caution.

In mice conditionally null for pten, observed low prostate AR protein expression was reversed following PI3K directed therapy (3). Additionally, this study found that the mRNA signature of AR activity (37) was elevated following PI3K pathway inhibition in the model system. Among 106 prostatectomy samples, the AR signature was repressed in cases with PTEN loss defined by either copy number change or transcript loss. Based on these data, our hypothesis was that high PI3K pathway activation would have been associated with both low AR staining and low AR pathway activity measured by mRNA expression. Instead, we found a strong positive correlation between our 4-marker PI3K signature and AR protein expression. This observation is in line with results from a small cohort of men in which pAKT staining was associated with increased AR staining in prostatectomy samples (47). Additionally, in LNCaP cells, inhibition of the PI3K pathway leads to decreased AR expression (48). Finally, in a cohort of more than 600 prostatectomy samples, AR was correlated with Ki67 staining (49), similar to our results. Our data from 309 prostate cancer samples demonstrated no relationship between the AR mRNA signature and protein staining or the IHC signature of PI3K activation. The explanation for this discordance is unclear, although it may be related to our definition of PI3K activity or tumor heterogeneity.

Across 1,021 samples, we found only 1.7% showed a completely concordant picture of low staining for PTEN and high staining for the remaining markers and 2.3% showing the reversed picture. Depending on the marker used, there have been wide-ranging estimates of PI3K dysfunction in prostate cancer. It seems likely that the very extremes of our 4-marker score are truly capturing some aspect or aspects of PI3K activation, but it is unclear what threshold should be used to call that pathway “active” or “inac-
tive” when using a combination of IHC markers that interrogate different portions of the pathway activated in potentially very different ways. Highlighting the possibility that our signature is identifying various pathways active in heterogeneous clinical samples (e.g., PI3K and mTOR) is the lack of expected strong correlation between staining of individual markers. Previous studies have also failed to find correlation between anticipated markers, including pS6, pAKT, and PTEN (38, 39, 50), suggesting the potential for complex interplay between these important pathways in clinical samples. Further, we were using a combina-
tion of samples from TURP and prostatectomy specimens poten-
tially introducing additional heterogeneity.

Lacking data from clinical trials using PI3K-targeted agents, it is unknown whether we selected the ideal panel of IHC markers to predict treatment response to targeted agents. We showed that pS6 and stathmin were best correlated with an mRNA signature of PTEN loss in breast cancer but comparisons to other published signatures could have also been made (19, 30). Although this was a large study using clinically meaningful outcomes, ours is not the first study to use multiple IHC markers to identify PI3K pathway.
activation and others have shown that combining markers in the pathway is more strongly associated with outcome than a single marker (43). Previous work has highlighted the heterogeneity of PTEN staining, for example, within a given prostate cancer (5), and one challenge is that we do not have a way to readily analyze this variability. What this heterogeneity means biologically or clinically and how to measure and record it across many samples is not known.

We hypothesized that we could simply and reliably determine PI3K pathway activation in prostate tumors using the combined staining of PTEN, pAKT, pS6, and stathmin. In over 1,000 archival samples, we found that the extremes of this 4-marker score were associated with both clinical and genetic features suggestive of PI3K activation. For men with higher Gleason scores, an increase in the PI3K pathway activity defined in this way was associated with an increased risk of developing lethal disease. We sought to identify which were the most important markers out of the four, and found that a combination of stathmin and pS6 was most correlated with a prior mRNA signature of pathway activity in breast cancer. This work raises several questions, including what threshold should be used to characterize a tumor as having the PI3K pathway active if assessed in this way; what if any clinical implications there are for the identified interaction between Gleason, the IHC score, and lethal outcome; whether other makers would be better at identifying pathway activation; and, ultimately, whether pathway activity and this signature in particular has any predictive value in men being treated with PI3K inhibitors. To date, clinically used predictive markers have included specific mutations, translocations, mRNA signatures, and IHC and further work in combination with clinical trial results will be needed to determine the utility of the markers we propose here.

In conclusion, a combination of PTEN, pAKT, pS6, and stathmin appears to capture PI3K pathway activity in prostate tumors as assessed by molecular and clinical features. Of the four, our data suggest that the combination of pS6 and stathmin may be equally good at determining activation.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
3. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarla-

Authors’ Contributions
Conception and design: N.E. Martin, J.A. Sinnott, O. Andrén, J.-E. Johansson, S. Finn, M. Loda
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): N.E. Martin, E.C. Stack, O. Andrén, S.-O. Andersson, J.-E. Johansson, M. Stampfer, L.A. Mucci, M. Loda
Analysis and interpretation of data (e.g., statistical analysis, biostatistics): N.E. Martin, T. Gerke, J.E. Stack, M. Fiorentino, S. Finn, P.W. Kantoff, M. Loda
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Gerke, S.-O. Andersson, G. Fedele, M. Loda
Study supervision: M. Loda

Acknowledgments
The authors are grateful to the participants in the Physicians’ Health Study, Health Professionals Follow-up Study, and Swedish Watchful Waiting Cohorts for their ongoing participation in the cohort. The authors also thank Greg Judson, Elizabeth Frost-Hawes, and Lauren McLaughlin for their research roles in follow-up of the cohort. The authors would like to thank the following state cancer registries for their help: AL, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. In addition, this study was approved by the Connecticut Department of Public Health (DPI) Human Investigations Committee. Certain data used in this publication were obtained from the DPI. The authors assume full responsibility for analyses and interpretation of these data.

Grant Support
This study was supported by grants P50CA090361-08 from the Dana-Farber/ Harvard Cancer Center Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, U1M1CA167552, R01CA141298, R01CA136578, R01CA131945, and P01CA80921 from the National Cancer Institute of the NIH, and the Prostate Cancer Foundation Young Investigator awards (to N.E. Martin, S. Finn, and L.A. Mucci).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 20, 2014; revised May 21, 2015; accepted June 12, 2015; published OnlineFirst June 29, 2015.
48. Martin et al.

Published OnlineFirst June 29, 2015; DOI: 10.1158/1541-7786.MCR-14-0569

Downloaded from mcr.aacrjournals.org on June 19, 2017. © 2015 American Association for Cancer Research.